ARIEL LOENESCU

We are developing a technology that will enable high-throughput drug screening for neurodegenerative disorders with a primary focus on neuromuscular diseases such as Amyotrophic Lateral Sclerosis (ALS). Our technology incorporates advanced neuromuscular tissue cultures with microfluidic elements and, unique electrode arrays for testing synapse function, and determining the optimal drug delivery site. This NMJ-MEA device could be optimized for various CNS synapse types, and by using patient-derived Induced Pluripotent Stem Cells (iPSCs), we aim to offer a novel personalized medicine platform for neurodegenerative patients.